(Q43649889)

25 November 2017

title

High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. (English)

1 reference

25 November 2017

3

1 reference

25 November 2017

10

1 reference

25 November 2017

Di Marco V

1

1 reference

25 November 2017

Vaccaro A

2

1 reference

25 November 2017

Alaimo G

4

1 reference

25 November 2017

Rodolico V

5

1 reference

25 November 2017

Parisi P

6

1 reference

25 November 2017

Peralta S

7

1 reference

25 November 2017

Di Stefano R

8

1 reference

25 November 2017

Almasio PL

9

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

Alimentary Pharmacology & Therapeutics

25 November 2017

published in

1 reference

25 November 2017

volume

15

1 reference

25 November 2017

issue

7

1 reference

25 November 2017

page(s)

953-958

1 reference

Clinical outcomes after transfusion-associated hepatitis C.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01005.X

10.1046/J.1365-2036.2001.01005.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference